Northwest Biotherapeutics, Inc.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Northwest Biotherapeutics, Inc. is a biotechnology company, which engages in the development of personalized immune therapies for cancer. It offers DCVax technology platform, which uses activated dendritic cells to mobilize a patient’s own immune system to attack their cancer. The company was founded by Alton L. Boynton on March 18, 1996 and is headquartered in Bethesda, MD.

BETHESDA, Md. , May 10, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that, as previously announced, a presentation entitled "Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Glioblastoma" will be made today at 11:10 a.m.

Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma Today At New York Academy of Sciences To Be Available Online As Well

BETHESDA, Md. , May 4, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that a presentation entitled "Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Glioblastoma" will be made on May 10, 2022 at 11:10 a.m.

Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma To Be Made At New York Academy Of Sciences

I have no great opinion about NWBO as a company.

Northwest Bio: What A Comparison Analysis Says About Its Progress

BETHESDA, Md., Feb. 17, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced commencement of production of its first dendritic cell cancer vaccine for a compassionate use patient at its recently licensed production facility in Sawston, UK.

Northwest Biotherapeutics Announces Commencement Of Cancer Vaccine Production At Its Sawston, UK Facility

New Oriental Education & Technology Group

Farmmi

Check these penny stocks out for your watchlist as 2021 ends The post Looking for Penny Stocks to Buy Now? 3 to Know About as 2021 Ends appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Looking for Penny Stocks to Buy Now? 3 to Know About as 2021 Ends

BETHESDA, Md., Dec. 21, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that approval has been received from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) of a license for manufacture of GMP (clinical grade) cell therapy products at its Sawston, UK facility.

Northwest Biotherapeutics Announces MHRA Approval Of License for GMP Manufacturing At Sawston, UK Facility

BETHESDA, Md., Nov. 29, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of a $15 million financing on November 22, 2021, which brought the Company's cash reserves above $20 million.

Northwest Biotherapeutics Announces $15 Million Financing

BETHESDA, Md., Oct. 28, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the completion of two key milestones which are required for production of DCVax products at the Company's manufacturing facility in Sawston, UK, and which have been a major focus since the completion of initial construction last year.

Northwest Biotherapeutics Announces HTA License Issued and MHRA Inspection Conducted for Sawston, UK Facility

Northwest Bio: Nowhere To Go But Up

CEL-SCI

CytoDyn Inc.

Generally speaking, biotech is a pretty innovative industry -- with a few notable bad apples.

3 Biotechs to Avoid Like the Plague in July

Acasti Pharma

Adamis Pharmaceuticals

Ampio Pharmaceuticals Inc

BIOLASE

Jaguar Health

Are these the best biotech penny stocks to watch right now? The post Best Biotech Penny Stocks In Summer 2021?

Best Biotech Penny Stocks In Summer 2021? 7 For Your Watchlist

Aerpio Pharmaceuticals Inc

Atossa Genetics

Globalstar

Ideanomics Inc

China Xiangtai Food Co Ltd

Senseonics Holdings

Looking for 7 penny stocks that could be buy the dip candidates? Check these out The post 7 Penny Stocks to Watch With Crypto News Sparking a Market Dip appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Penny Stocks to Watch With Crypto News Sparking a Market Dip

BETHESDA, Md., May 12, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that an application for certification of the manufacturing facility in Sawston, UK has been submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA).

UK Manufacturing Facility & Phase III Trial Updates From Northwest Biotherapeutics (OTCQB: NWBO)

BETHESDA, Md., March 16, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that development of the initial production capacity of the Company's Sawston, UK advanced manufacturing facility has been completed and the facility is now in the final stages of preparation for an application for certification by the UK Medicines and Health Products Regulatory Authority ("MHRA").

Northwest Biotherapeutics Announces Development Completed for Initial Production Capacity of Sawston, UK Facility

NWBO has finally arrived at its endgame, and it must announce either positive or negative pivotal data very soon, no later than 2021. The company has managed to secure some funding.

Northwest Bio: The Endgame Is Approaching

NWBO has run an 18-year long trial in GBM, one of the deadliest of cancers. It has been mired in controversies, and it has no cash.

Northwest Biotherapeutics: Blinded By The Dazzle Of The Unblinding

Novocure

In a short period of time, this immunotherapy biotech could either become a multi-bagger or trade near $0.

Is Northwest Biotheraputics a Buy Ahead of Its Brain Tumor Vaccine Clinical Data Release?

With Data Lock just announced, Top Line Date is imminent.

Northwest Bio, Wow!

News for Northwest Biotherapeutics, Inc. Stock (NWBO)